Moving Beyond the 12-Month Default: Personalized DAPT Duration Proven Superior in the PARTHENOPE Trial

Highlights

The PARTHENOPE trial provides landmark evidence for the clinical superiority of individualized dual antiplatelet therapy (DAPT) strategies. The key findings include:

• Personalizing DAPT duration between 3 and 24 months based on validated risk scores significantly reduced the primary endpoint of Net Adverse Clinical Events (NACE) at 24 months compared to a fixed 12-month regimen.
• The benefit was primarily driven by a significant reduction in ischemic complications, specifically myocardial infarction (MI) and urgent target vessel revascularization (TVR).
• Importantly, the personalized approach did not lead to a statistically significant increase in major bleeding events (BARC type 2, 3, or 5) compared to the standard 12-month therapy.
• These results challenge the conventional 12-month ‘one-size-fits-all’ DAPT standard, suggesting that a precision-medicine approach to antithrombotic duration optimizes the balance between ischemic and hemorrhagic risks.